Base period - maintenance services for government-owned illumina novaseq 6000 sequencer in support of NIH/NCI/CCR/laboratory of pathology
Ended Purchase Order Awarded Last action
- Contract number
- 75N91024P00364
- Awardee
-
Illumina, Inc. UEI KMW3CRWNAAF3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $134,247
Award facts
- Opportunity
-
- Preventive Maintenance Services for NovaSeq 6000 (Silver Support Plan) Solicitation · 75N91024Q00031 · Posted Feb 8, 2024
- Contract value 100% obligated
- $134,247.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 811210 Electronic and Precision Equipment Repair and Maintenance
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20892, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Original award | $134,247 |
About this award
This firm fixed-price purchase order contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for maintenance services on a government-owned Illumina NovaSeq 6000 sequencing instrument. The $134,247.36 contract provides annual preventive maintenance, emergency repair, software/firmware updates, replacement parts, and technical support for the sequencing system located at the NCI's Laboratory of Pathology in Bethesda, Maryland. The contract has a performance period from August 1, 2024 through July 31, 2025, with the potential for continued annual renewals through July 2029. This sole-source award to Illumina, the original equipment manufacturer, is required to maintain optimal performance and data integrity for clinical sequencing assays supporting patient enrollment in NCI clinical trials and treatments. There is no set-aside designation for this commercial item acquisition.
Quick answers
Who was awarded contract 75N91024P00364?
75N91024P00364 was awarded to Illumina, Inc. by National Cancer Institute (National Institutes of Health) on August 1, 2024.
How much is contract 75N91024P00364 worth?
The government has obligated $134,247 on 75N91024P00364.
Was contract 75N91024P00364 competed?
The extent of competition for 75N91024P00364 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award